Status: Recruiting
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.
Participants needed: 21
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Jordan KharofaUpdated: Feb 27, 2026Locations: 1
Eligibility criteria
Age ≥18 years. [+8]
Patients with prior immunotherapy use in the adjuvant setting for NSCLC or Melan... [+4]